173 related articles for article (PubMed ID: 24350356)
21. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
22. [Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
Nishida T; Yoshidome K; Tori M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():452-6. PubMed ID: 23513883
[No Abstract] [Full Text] [Related]
23. Remission status should not be treated as a base-line covariate--reply to Etienne et al.
Lauseker M; Hasford J
Haematologica; 2014 Sep; 99(9):e174-5. PubMed ID: 25176984
[No Abstract] [Full Text] [Related]
24. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
Ray-Coquard I; Blay JY
Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
[No Abstract] [Full Text] [Related]
25. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
26. Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome.
Xu XH; Huang LS; Yang J; Yu T; Tong JF; Yuan XG; Zhao XY
Leuk Lymphoma; 2013 Jan; 54(1):195-7. PubMed ID: 22574970
[No Abstract] [Full Text] [Related]
27. Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report.
Sanford M; Scott LJ
BioDrugs; 2011 Jun; 25(3):191-2. PubMed ID: 21627342
[No Abstract] [Full Text] [Related]
28. Transporter pumps and imatinib: a cause of pharmacokinetic resistance?
Klumpen HJ; Liddle C; Gurney H
Cancer Biol Ther; 2008 Mar; 7(3):416-8. PubMed ID: 18334863
[No Abstract] [Full Text] [Related]
29. Cancer treatment. New drugs, new hope.
Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447
[No Abstract] [Full Text] [Related]
30. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
Zheng S; Jia J; Pan YL; Tao DY; Lu HS
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
[No Abstract] [Full Text] [Related]
31. Bone metabolism during long-term treatment with imatinib.
O'Sullivan S; Horne A; Wattie D; Porteous F; Gamble G; Browett P; Grey A
Leuk Lymphoma; 2013 Aug; 54(8):1783-5. PubMed ID: 23278638
[No Abstract] [Full Text] [Related]
32. [Mechanisms of resistance to BCR-ABL kinase inhibitors].
Diamond J; da Silva MG
Acta Med Port; 2013; 26(4):402-8. PubMed ID: 24016650
[TBL] [Abstract][Full Text] [Related]
33. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
34. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
[TBL] [Abstract][Full Text] [Related]
35. Is anticancer drug development heading in the right direction?
Hambley TW; Hait WN
Cancer Res; 2009 Feb; 69(4):1259-62. PubMed ID: 19208831
[TBL] [Abstract][Full Text] [Related]
36. Current management of GISTs.
Blanke C
Clin Adv Hematol Oncol; 2010 May; 8(5):334. PubMed ID: 20551892
[No Abstract] [Full Text] [Related]
37. The role of imatinib plasma level testing in gastrointestinal stromal tumor.
George S; Trent JC
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S45-50. PubMed ID: 21140148
[TBL] [Abstract][Full Text] [Related]
38. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
39. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor.
Hamza I; Gaies E; Kastalli S; Daghfous R; El Aidli S
Therapie; 2014; 69(3):245-7. PubMed ID: 24934821
[TBL] [Abstract][Full Text] [Related]
40. [Imatinib--a new perspective in the treatment of tumors].
Klener P; Klamová H
Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
